Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
Price : $35 *
At a glance
- Drugs F-18 fluorothymidine (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Diagnostic use
- 31 Aug 2018 Biomarkers information updated
- 02 Jun 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Status changed from recruiting to active, no longer recruiting.